ArticleFrontiers in medicine2020
Lung Involvement in Primary Sjögren's Syndrome-An Under-Diagnosed Entity.
Article in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease.The European respiratory journal · 2026Guideline
- Clinical features, diagnosis, and treatment of primary Sjögren's disease with interstitial lung disease: A narrative review.Frontiers in immunology · 2026Review
- Identification of novel autoantibodies in Sjögren's disease.Frontiers in immunology · 2025Article
- Prevalence of Interstitial Lung Disease in Patients with Primary Sjogren's Syndrome: A Systematic Review and Meta-analysis of Observational Studies : Prevalence of Interstitial Lung Disease in Patients with Primary Sjogren's Syndrome.Galen medical journal · 2025Review
- Article
- Interstitial Lung Disease Phenotypes and Predictive Risk Factors in Primary Sjögren's Syndrome.Journal of clinical medicine · 2024Article
- Clinical Characteristics and Outcomes of Interstitial Lung Disease in Primary Sjögren's Syndrome: A Retrospective Cohort Study.Mediterranean journal of rheumatology · 2024Article
- Article
- Manifestations and management of Sjögren's disease.Arthritis research & therapy · 2024Review
- The Spectrum of Extraglandular Manifestations in Primary Sjögren's Syndrome.Journal of personalized medicine · 2023Review
- Sjögren's syndrome with and without neurological involvement.Journal of neurology · 2023Article
- [Practicable diagnostics of Sjögren's syndrome in interstitial lung disease-A discussion article].Zeitschrift fur Rheumatologie · 2023Article
- Interstitial Lung Disease and Pulmonary Damage in Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2023Review
- Organizing pneumonia as presenting feature of primary Sjögren's syndrome: A case report.Respiratory medicine case reports · 2023Article
- Pulmonary involvement in primary Sjögren's syndrome: contribution of the different means in the systematic investigation.The Pan African medical journal · 2023Article
- Saliva Free Light Chains in Patients with Neuro-Sjögren.Biomedicines · 2022Article
- Sjögren's Syndrome-Related Organs Fibrosis: Hypotheses and Realities.Journal of clinical medicine · 2022Review
- Radiological patterns and pulmonary function values of lung involvement in primary Sjögren's syndrome: A pilot analysis.Frontiers in medicine · 2022Article
- Multimodal Assessment and Characterization of Sicca Syndrome.Frontiers in medicine · 2021Article
- Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders.Therapeutic advances in musculoskeletal disease · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interstitial lung disease (ILD) represents a frequent extra-glandular manifestation of primary Sjögren's Syndrome (pSS). Limited published data regarding phenotyping and treatment exists. Advances in managing specific ILD phenotypes have not been comprehensively explored in patients with coexisting pSS. This retrospective study aimed to phenotype lung diseases occurring in a well-described pSS-ILD cohort and describe treatment course and outcomes. Between April 2018 and February 2020, all pSS patients attending our Outpatient clinic were screened for possible lung involvement. Clinical, laboratory and high-resolution computed tomography (HRCT) findings were analyzed. Patients were classified according to HRCT findings into five groups: usual interstitial pneumonia (UIP), non-specific interstitial pneumonia (NSIP), desquamative interstitial pneumonia (DIP), combined pulmonary fibrosis and emphysema (CPFE), and non-specific-ILD. Lung involvement was confirmed in 31/268 pSS patients (13%). One-third (10/31) of pSS-ILD patients were Ro/SSA antibody negative. ILD at pSS diagnosis was present in 19/31 (61%) patients. The commonest phenotype was UIP
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.